EGFR-Mutant NSCLC: Spotlight on Amivantamab

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
• Epidermal growth factor receptor (EGFR) mutations are key drivers in a subset of NSCLC patients.
• Targeted therapies have significantly improved outcomes, but resistance and unmet needs persist.

Purpose of the Study:

• To evaluate the efficacy and safety of amivantamab, an EGFR-MET bispecific antibody, in patients with EGFR-mutant non-small cell lung cancer.
• To assess amivantamab in combination with chemotherapy as a first-line treatment for specific EGFR mutations.
• To compare amivantamab-based regimens with standard-of-care treatments like osimertinib.

Main Methods:

• Analysis of data from three Phase III clinical trials: PAPILLON, MARIPOSA, and MARIPOSA-2.
• Investigated amivantamab as a monotherapy and in combination with chemotherapy and/or lazertinib.
• Compared outcomes including progression-free survival (PFS) and toxicity profiles against standard treatments.

Main Results:

• Amivantamab combined with chemotherapy demonstrated superior first-line efficacy in patients with EGFR exon 20-mutated NSCLC.
• In other EGFR-mutant NSCLC subsets, amivantamab in combination with or without lazertinib showed improved PFS compared to standard osimertinib.
• These combination strategies were associated with increased toxicity.

Conclusions:

• Amivantamab-based regimens represent a potential new standard of care for EGFR-mutant NSCLC.
• The combination of amivantamab and chemotherapy is a highly effective first-line option for the exon 20 mutation subset.
• Further evaluation of toxicity management is warranted for broader application of amivantamab combinations.